Teradyne stock price jumps after Q4 beat, AI test demand lifts outlook

Teradyne stock price jumps after Q4 beat, AI test demand lifts outlook

New York, Feb 3, 2026, 18:39 EST — After-hours

  • Teradyne shares climbed in late after-hours trading following the company’s quarterly results and an upbeat forecast for the first quarter.
  • Compute and memory testing tied to AI led the charge, with the stock’s back-and-forth underscoring just how closely investors are watching the cycle.
  • Attention turns to Wednesday’s open and the latest analyst notes released after the earnings call.

Teradyne shares jumped roughly 13% to $282.98 in after-hours trading Tuesday, following a volatile day where prices swung from $249.54 to $312.14. Around 11.8 million shares traded hands.

The North Reading company reported to investors via Business Wire that fourth-quarter revenue hit $1.083 billion, with adjusted (non-GAAP) earnings per share coming in at $1.80. It projects first-quarter revenue between $1.15 billion and $1.25 billion, and adjusted EPS ranging from $1.89 to $2.25. CEO Greg Smith attributed the boost to strong AI-driven demand. Non-GAAP figures exclude items like restructuring charges and amortization. (Business Wire)

Why it matters now: test-equipment makers offer an early glimpse into chip production ramps since every advanced device needs testing before shipment. With AI hardware spending still uneven, investors are snapping up any guidance or clues about the cycle’s true breadth.

Wall Street had tempered expectations ahead of the report. Investors Business Daily noted analysts anticipated adjusted EPS of $1.38 on $977 million in sales for the fourth quarter, with the current quarter seen delivering around $1.29 per share on $939 million in revenue. Following the release, the stock jumped over 20% in early extended trading, after gaining roughly 3.5% during the regular session. (Investors)

Several brokers wasted no time updating their targets. Evercore ISI Group hiked its price target to $280 from $200, sticking with an outperform rating. Cantor Fitzgerald also raised its target, this time to $270 from $240, while maintaining an overweight rating, Benzinga data showed. (Benzinga)

Investing.com flagged a separate note from Cantor, which called the quarter “a significant beat and raise.” The firm highlighted an earnings run-rate close to $8 per share spanning the fourth and first quarters. Cantor also flagged that more details should emerge as the company fleshes out its 2026 outlook. (Investing)

The results were also submitted to the U.S. Securities and Exchange Commission in a Form 8-K. CFO Michelle Turner signed the filing, which names the Nasdaq Stock Market LLC as the stock’s main trading venue. (Securities and Exchange Commission)

Teradyne’s investor relations calendar confirmed the earnings conference call took place earlier Tuesday. Links for the webcast, transcript, and presentation materials were posted online. (Teradyne, Inc.)

However, the company warned of familiar challenges: demand might drop if the economy weakens or if major clients postpone purchases. Export controls and tariffs could also disrupt shipments and complicate planning. It flagged execution risks tied to new product launches and expanding its robotics division. (Securities and Exchange Commission)

The real test arrives Wednesday at the regular-session open, as the after-hours surge hits cash-market liquidity. Traders will watch closely to see if the rally holds when updated models and fresh price targets begin to circulate.

Stock Market Today

  • Novo Nordisk Shares Drop 14.75% on Weaker 2026 Outlook Amid Obesity-Drug Market Pressure
    February 3, 2026, 8:15 PM EST. Novo Nordisk shares plunged 14.75% to $50.33 after management projected a 2026 sales and profit decline, despite recent strong results. The Danish drugmaker faces pricing pressure and rising competition in obesity treatments, particularly in the U.S. Trading volume surged to 67.7 million shares, nearly triple the average. The company forecasts a 5%-13% sales drop in 2026, driven by price cuts, patent expirations, and intensified rivalry. Meanwhile, pharma peers Eli Lilly and Novartis also closed lower amid broader sector weakness. Investors will monitor Novo Nordisk's strategy expansion and new therapies like the Wegovy pill as key to restoring growth momentum.
IBM stock price slides after-hours as AI disruption fears rattle software and consulting shares
Previous Story

IBM stock price slides after-hours as AI disruption fears rattle software and consulting shares

Lumentum stock jumps after earnings beat, AI optics demand lifts outlook
Next Story

Lumentum stock jumps after earnings beat, AI optics demand lifts outlook

Go toTop